- Home
- BIIB vs DECK Comparison
BIIB vs DECK Comparison
Compare BIIB & DECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- DECK
- Stock Information
- Founded
- BIIB 1978
- DECK 1973
- Country
- BIIB United States
- DECK United States
- Employees
- BIIB N/A
- DECK N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- DECK Shoe Manufacturing
- Sector
- BIIB Health Care
- DECK Consumer Discretionary
- Exchange
- BIIB Nasdaq
- DECK Nasdaq
- Market Cap
- BIIB 18.8B
- DECK 15.2B
- IPO Year
- BIIB 1991
- DECK 1993
- Fundamental
- Price
- BIIB $132.82
- DECK $106.21
- Analyst Decision
- BIIB Buy
- DECK Buy
- Analyst Count
- BIIB 27
- DECK 22
- Target Price
- BIIB $188.17
- DECK $144.56
- AVG Volume (30 Days)
- BIIB 1.3M
- DECK 2.9M
- Earning Date
- BIIB 07-31-2025
- DECK 07-24-2025
- Dividend Yield
- BIIB N/A
- DECK N/A
- EPS Growth
- BIIB 26.39
- DECK 30.25
- EPS
- BIIB 10.12
- DECK 6.33
- Revenue
- BIIB $9,816,400,000.00
- DECK $4,985,612,000.00
- Revenue This Year
- BIIB N/A
- DECK $10.38
- Revenue Next Year
- BIIB N/A
- DECK $7.85
- P/E Ratio
- BIIB $13.13
- DECK $16.78
- Revenue Growth
- BIIB 1.59
- DECK 16.27
- 52 Week Low
- BIIB $110.04
- DECK $93.72
- 52 Week High
- BIIB $238.00
- DECK $223.98
- Technical
- Relative Strength Index (RSI)
- BIIB 59.57
- DECK 49.40
- Support Level
- BIIB $123.90
- DECK $102.09
- Resistance Level
- BIIB $134.75
- DECK $109.08
- Average True Range (ATR)
- BIIB 3.50
- DECK 2.95
- MACD
- BIIB 0.28
- DECK 0.86
- Stochastic Oscillator
- BIIB 83.71
- DECK 75.17
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and about 180 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.